Last updated: February 20, 2026
What is the indicated use of NDC 62135-0671?
NDC 62135-0671 corresponds to Difelikefalin (Korsuva), a peripherally restricted kappa-opioid receptor agonist approved by the FDA in August 2021 for moderate-to-severe pruritus in adult patients with chronic kidney disease undergoing hemodialysis. Difelikefalin addresses a significant unmet need in this patient population with limited treatment options.
What is the current market landscape for Difelikefalin?
Market Size and Demand Drivers
- Chronic Kidney Disease (CKD) in Hemodialysis Patients: Estimated 468,000 adults in the U.S. on dialysis as of 2022 (USRDS Data).
- Prevalence of Pruritus in CKD: Reports suggest 60-70% of dialysis patients experience pruritus, with approximately 50% rating it as severe (K/DOQI guidelines, 2020).
- Market Penetration: Difelikefalin's initial uptake remains modest; early prescriptions suggest a slow ramp due to limited awareness, existing treatment limitations, and cost factors.
Competitive Landscape
- No FDA-approved therapies directly target CKD-associated pruritus.
- Off-label treatments include antihistamines, gabapentinoids, corticosteroids, and phototherapy with limited efficacy.
- The market has a high unmet need but faces challenges from provider awareness and reimbursement pathways.
Market Penetration Data (2022–2023)
| Indicator |
Data |
Source |
| Total dialysis population (US) |
468,000 |
USRDS [1] |
| Estimated pruritus prevalence |
60-70% |
K/DOQI [2] |
| Eligible patients for treatment |
200,000+ |
Calculated |
| Prescriptions in Q3 2023 |
Approx. 10,000 |
IQVIA [3] |
What are the price projections for NDC 62135-0671?
Current Pricing
- Average wholesale price (AWP): Approximately $850 per 8 mcg dose; smaller doses are proportional.
- Estimated monthly costs: For chronic use, this translates to roughly $2,550-$3,400 per patient, assuming daily dosing.
Future Price Trends
- Market Entry Price: Expected initial listing at $850 per dose, aligning with similar injectable specialty drugs.
- Potential Discounts: Payers and PBMs could negotiate discounts, reducing net prices by 20-30%.
- Reimbursement Factors: Medicare and commercial payers have begun coverage discussions; approved billing codes are in place.
Price Outlook Over 5 Years
| Year |
Estimated Price per Dose |
Factors Influencing Price |
Notes |
| 2023 |
$850 |
Initial launch, limited competition |
Launch pricing reflects niche market |
| 2024 |
$800–$850 |
Entry of competitors, payer negotiations |
Slight decline possible |
| 2025 |
$750–$800 |
Increased competition or biosimilar entry |
Price pressure intensifies |
| 2026 |
$700–$750 |
Routine negotiation, expanded access |
More formulary approvals |
| 2027 |
$650–$700 |
Payer discounts, volume-based agreements |
Stable but declining trend |
Risks to Price Stability
- Entry of alternative palliative therapies or generics.
- Reimbursement changes or policy shifts.
- Competitive pressure from emerging drugs or biosimilars.
What factors influence market growth and penetration?
- Physician awareness: Growth depends on continued education about the drug’s efficacy.
- Reimbursement and access: Payer policies significantly affect prescription volume.
- Patient adherence: Difelikefalin’s safety profile and administration logistics impact acceptance.
- Pricing strategy: Payer negotiations and discounts shape overall revenue potential.
What are the regulatory and strategic considerations?
- The drug’s novel mechanism ensures no direct biosimilar competition soon.
- FDA approval expanded access pathways encourage broader utilization.
- Integration into dialysis clinics could enhance market penetration.
Summary of key economic assumptions and projections
| Metric |
Assumption |
Source |
| Annual sales (2025) |
$300 million |
Estimated from market size and penetration rates |
| CAGR (2023–2027) |
15% |
Based on unmet need and early uptake trends |
| Price decline |
10% over 3 years |
Negotiation and competitive pressures |
Key Takeaways
- Difelikefalin addresses an unmet need in CKD-associated pruritus.
- Market size is approximately 200,000+ eligible U.S. patients.
- Initial pricing around $850 per dose; expects gradual decline with increased competition.
- Prescriptions remain limited but are likely to grow steadily over five years.
- Future revenue depends on payer acceptance, clinical adoption, and competitive dynamics.
Frequently Asked Questions
1. When might Difelikefalin reach peak market penetration?
Within 3–5 years, contingent on increased physician awareness and payer coverage.
2. How could biosimilar or alternative therapies impact prices?
Introduction of biosimilars or competing drugs could reduce prices 20–30% over time.
3. What are the major barriers to market growth?
Limited physician familiarity, reimbursement challenges, and logistical hurdles in dialysis clinics.
4. How does the drug’s pricing compare to other specialty injectables?
Its starting price is comparable or slightly higher than similar drugs like erythropoietin-stimulating agents but aligned with specialty drug market norms.
5. What is the anticipated FDA reauthorization or label expansion potential?
Potential expansion to other pruritus-related conditions, pending further clinical trials.
References
[1] USRDS. (2022). US Renal Data System. Annual Data Report.
[2] K/DOQI. (2020). Clinical Practice Guidelines for CKD-associated pruritus.
[3] IQVIA. (2023). National Prescription Data Reports.
